Quince Therapeutics (QNCX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Annual meeting scheduled for June 11, 2026, with voting open until June 10, 2026, at 11:59 PM ET.
Shareholders can access proxy materials online or request paper/email copies by May 28, 2026.
Virtual meeting access and in-person voting options are available, with specific instructions for legal proxy requests.
Voting matters and shareholder proposals
Election of June Bray as Class I director nominee to serve until the 2029 annual meeting.
Approval sought for a reverse stock split at a ratio between one-for-ten and one-for-one-hundred.
Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation for named executive officers.
Approval to adjourn or postpone the meeting if further solicitation of proxies is needed.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director election and corporate actions.
Latest events from Quince Therapeutics
- Key votes include a reverse stock split, director election, and auditor ratification to support compliance.QNCX
Proxy filing27 Apr 2026 - Shareholders will vote on a reverse stock split, auditor ratification, and executive compensation.QNCX
Proxy filing17 Apr 2026 - Lead asset failed in Phase 3, triggering strategic review and raising going concern risks.QNCX
Q4 202510 Apr 2026 - Pivotal Phase III EryDex trial in A-T targets $1B+ market, topline results due Q4 2025.QNCX
The ThinkEquity Conference 20243 Feb 2026 - Phase III data for a chronic steroid therapy in rare disease expected Q4, with strong safety and market potential.QNCX
The Citizens JMP Life Sciences Conference 20253 Feb 2026 - EryDex's phase III trial targets a $1B+ rare disease market with broad expansion potential.QNCX
LD Micro Main Event XVII18 Jan 2026 - Biotech seeks up to $200M, including $75M at-the-market, to fund R&D and operations.QNCX
Registration Filing16 Dec 2025 - Biotech registers resale of 17.3M shares after $11.5M private placement to fund rare disease therapy.QNCX
Registration Filing16 Dec 2025 - Red blood cell-encapsulated steroid therapy nears pivotal data in AT, targeting major rare disease markets.QNCX
Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202516 Dec 2025